DnB Asset Management
MRNA icon

DnB Asset Management’s Moderna MRNA Stock Holding History

DnB Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39M Sell
48,448
-3,453
-7% -$179K 0.01% 548
2026
Q1 		$2.64M Buy
+51,901
New +$2.42M 0.01% 557
2025
Q2 		– Sell
-60,875
Closed -$1.73M – 753
2025
Q1 		$1.73M Buy
60,875
+3,120
+5% +$111K 0.01% 593
2024
Q4 		$2.4M Buy
57,755
+2,865
+5% +$137K 0.01% 549
2024
Q3 		$3.67M Buy
54,890
+1,930
+4% +$177K 0.02% 444
2024
Q2 		$6.29M Buy
52,960
+1,047
+2% +$132K 0.03% 311
2024
Q1 		$5.53M Sell
51,913
-10,288
-17% -$1.04M 0.03% 337
2023
Q4 		$6.19M Sell
62,201
-48,280
-44% -$4.06M 0.03% 320
2023
Q3 		$11.4M Buy
110,481
+43,337
+65% +$4.83M 0.07% 212
2023
Q2 		$8.16M Buy
67,144
+2,615
+4% +$349K 0.05% 272
2023
Q1 		$9.91M Buy
64,529
+2,941
+5% +$485K 0.06% 236
2022
Q4 		$11.1M Buy
61,588
+578
+0.9% +$94.5K 0.08% 207
2022
Q3 		$7.21M Buy
61,010
+458
+0.8% +$69.5K 0.06% 263
2022
Q2 		$8.65M Buy
60,552
+2,068
+4% +$296K 0.06% 238
2022
Q1 		$10.1M Buy
58,484
+4,861
+9% +$818K 0.06% 243
2021
Q4 		$13.6M Buy
53,623
+6,008
+13% +$1.76M 0.08% 195
2021
Q3 		$18.3M Buy
47,615
+4,959
+12% +$1.83M 0.12% 154
2021
Q2 		$10M Buy
42,656
+4,477
+12% +$800K 0.07% 223
2021
Q1 		$5M Buy
38,179
+165
+0.4% +$23.9K 0.04% 319
2020
Q4 		$3.97M Buy
38,014
+4,685
+14% +$474K 0.03% 315
2020
Q3 		$2.36M Buy
33,329
+2,332
+8% +$163K 0.03% 377
2020
Q2 		$1.99M Buy
+30,997
New +$1.7M 0.02% 388

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

DnB Asset Management's MRNA Position: Q2 2026 in Review

DnB Asset Management reduced its Moderna (MRNA) stake by 6.7% in Q2 2026, selling an estimated $179K and leaving 48,448 shares worth $3.39M. The position accounts for 0.01% of the portfolio, ranked #548.

DnB Asset Management first reported a position in MRNA in Q2 2020 and has held it in 22 quarters since. The position peaked at $18.3M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • DnB Asset Management held 48,448 shares of Moderna worth $3.39M as of Q2 2026.
  • DnB Asset Management sold 3,453 Moderna shares in Q2 2026, an estimated $179K.
  • Moderna made up 0.01% of DnB Asset Management's portfolio in Q2 2026, its #548 holding.
  • DnB Asset Management first reported a position in Moderna in Q2 2020 and has held it in 22 quarters since.
  • DnB Asset Management's Moderna position peaked at $18.3M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.